Connect with us


This machine saving lives of severe Covid patients: Study



Researchers have revealed that Continuous Positive Airway Pressure (CPAP) machines — the existing medical treatment — are saving lives of patients hospitalised with Covid-19.

CPAP machines use mild air pressure to keep the airways open and are typically used by patients who have breathing problems during sleep.

“We show that Continuous Positive Airway Pressure (CPAP) in the first days of hospitalisation seems to save between 10 per cent to 20 per cent of patients,” said study author Luigi Sedda of Lancaster University in the UK.

“However, it is important to underline that this was a pilot study with a small sample size, although comforting evidence is starting to emerge elsewhere,” Sedda added.

For the study, published in the journal BMJ Respiratory Open, the research team used the CPAP machines on patients with Covid-19 admitted to the Royal Albert Edward Infirmary in Wigan.

In the case of patients with the severe acute respiratory syndrome, Covid-19 may cause the lungs to swell and collapse.

Using CPAP treatment, which is often used at home to help people with sleep problems, helps to keep the lungs open and makes breathing easier.

The research conducted by the team showed how CPAP treatment can be delivered effectively in a ward setting, with low resources both across the country and worldwide where intensive care bed availability is limited.

The research has so far helped almost a hundred patients.

“When you use CPAP early in the admission it stops the patient getting worse, therefore avoiding invasive ventilation techniques,” said study author Abdul Ashish.

“As CPAP is readily available and can be used in a ward setting, we have demonstrated that, when used early, it can be a very effective way of treating severe Covid-19 pneumonia,” Ashish added.

The researchers also found that the early use of CPAP potentially reduces lung damage during the worst of the Covid-19 infection and allows the patient to recover from the inflammatory effects.

However, when used later, CPCP does not prevent lung damage thus leading to additional inflammation and a reduction in survival chances.

“We are at the forefront of developing care for Covid-19 patients and have developed a very effective treatment strategy for our population who develop lung failure following Covid-19 infection,” the researchers wrote.

Continue Reading


447 cases of adverse effect reported,Covid-19 vaccine given to 2,24,301 beneficiaries :Govt.



A total of 2,24,301 beneficiaries have been inoculated with COVID-19 vaccine so far, out of which only 447 adverse events following immunisation (AEFI) were reported, the Union Health Ministry said on day two of the nationwide vaccination drive on Sunday.

Addressing a press briefing, the ministry’s Additional Secretary Manohar Agnani said out of the 447 adverse events following immunisation, only three required hospitalisation.

“Today being Sunday, only six states conducted vaccination drive and in 553 sessions a total of 17,072 beneficiaries were vaccinated,” he said.

The six states where the vaccination drive was carried out on Sunday are Andhra Pradesh, Arunachal Pradesh, Karnataka, Kerala, Manipur and Tamil Nadu, he added.

Agnani said a total of 2,24,301 beneficiaries have been vaccinated till January 17 as per provisional reports, adding that 2,07,229 of them received the jabs on day one of the drive.

“A total of 447 AEFI have been reported on January 16 and 17, out of which only three required hospitalisation. Most of the AEFI reported so far are minor like fever, headache, nausea,” he said.

He said a meeting was held with all states and union territories on Sunday to review the progress of the drive, identify bottlenecks and plan corrective actions.

Prime Minister Narendra Modi rolled out the world’s largest inoculation drive against COVID-19 on Saturday and said the two vaccines being deployed will ensure a “decisive victory” for India against the pandemic.

India has approved two vaccines—Covaxin developed by Bharat Biotech and Covishield from the Oxford/AstraZeneca stable being manufactured by the Serum Institute of India—for emergency use in the country.

According to the government, the shots will be offered first to an estimated one crore healthcare workers and around two coror frontline workers, and then to persons above 50 years of age, followed by persons younger than 50 years of age with associated comorbidities. PTI

Continue Reading